title: Human papillomavirus genotyping by 454 next generation sequencing technology.
abstract: BACKGROUND
  An accurate tool for human papillomavirus (HPV) typing is important both for management of patients with HPV infection and for surveillance studies.
  
  
  OBJECTIVE
  Design and evaluation of an HPV typing method based on 454 next generation sequencing (NGS) technology.
  
  
  METHODS
  Development of an HPV typing method based on 454 NGS of HPV L1 amplicons generated with MY09/11-based primers. Evaluation of the NGS method in control samples and in a panel of cervical cytological samples. Comparison of the NGS typing method with cycle sequencing and with the reverse hybridization-based INNO-LiPA HPV Genotyping Extra assay (LiPA).
  
  
  RESULTS
  In control samples carrying mixtures of HPV16 and HPV18 DNA, the NGS method could reliably detect genotype sequences occurring at a frequency of 1% in multiple infections with a sensitivity of 100 genome equivalents/μL. In cervical cytology samples, comparison with cycle sequencing demonstrated accuracy of HPV typing by NGS. The NGS method had however lower sensitivity for some HPV types than LiPA, conceivably due to the poor sensitivity of the MY09/11-based primers. At variance, LiPA could not detect HPV types which were present in low proportion in multiple infections (<10% of HPV reads obtained by NGS). In addition, NGS allowed identifying the presence of different variants of the same HPV type in a specimen.
  
  
  CONCLUSIONS
  NGS is a promising method for HPV typing because of its high sensitivity in multiple infection and its potential ability to detect a broad spectrum of HPV types, subtypes, and variants.
authors.affiliation: Department of Histology, Microbiology, and Medical Biotechnologies, University of Padova, Padova, Italy. luisa.barzon@unipd.it
authors.forename: Luisa
authors.initials: L
authors.lastname: Barzon
authors.forename: Valentina
authors.initials: V
authors.lastname: Militello
authors.forename: Enrico
authors.initials: E
authors.lastname: Lavezzo
authors.forename: Elisa
authors.initials: E
authors.lastname: Franchin
authors.forename: Elektra
authors.initials: E
authors.lastname: Peta
authors.forename: Laura
authors.initials: L
authors.lastname: Squarzon
authors.forename: Marta
authors.initials: M
authors.lastname: Trevisan
authors.forename: Silvana
authors.initials: S
authors.lastname: Pagni
authors.forename: Federico
authors.initials: F
authors.lastname: Dal Bello
authors.forename: Stefano
authors.initials: S
authors.lastname: Toppo
authors.forename: Giorgio
authors.initials: G
authors.lastname: Palù
mesh_terms: D036022:Capsid Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D060005:Genotyping Techniques / Q000379:methods*; D006367:HeLa Cells; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods*; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000235:genetics; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics*; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA / Q000379:methods*
chemical_list: D036022:Capsid Proteins; C114580:HPV L1 protein, Human papillomavirus; D009856:Oncogene Proteins, Viral